Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CRISPR Therapeutics AG (CRSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT-"
05/08/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results"
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/15/2022 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Top-line data expected to report in 1H2022 for ongoing CTX120™and CTX130™ clinical trials- -First patient dosed in Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes - ZUG, Switzerland and CAMBRIDGE, Mass., February 15, 2022"
11/03/2021 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia and sickle cell disease ; regulatory submissions planned for late 2022- -Reported positive results from the ongoing Phase 1 CARBON clinical trial evaluating the safety and efficacy of CTX110™ for CD19+ B-cell malignancies; enrollment continues, with potential registrational trial incorporating consolidation dosing expected to initiate in Q1 2022- -Implementing consolidation dosing protocols for CTX120™ and CTX130™ clinical trials; enrollment continues, with top-line data expected to report in 1H 2022- -Regenerative medicine and in vivo programs continue to progress and remain on track- ZUG, Switzerland and CAMBRIDGE, Mass.,..."
07/29/2021 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-"
02/16/2021 8-K Quarterly results
10/28/2020 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results -Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-"
07/27/2020 8-K Quarterly results
04/28/2020 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results -Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies-"
02/12/2020 8-K Quarterly results
10/28/2019 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results -Provides update from ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies-"
07/29/2019 8-K Quarterly results
04/29/2019 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results -Enrollment ongoing in Phase 1/2 clinical trials of CTX001™ for patients with severe hemoglobinopathies-"
02/25/2019 8-K Quarterly results
11/07/2018 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results -Initiated Phase 1/2 Clinical Trial of CTX001 in β-thalassemia-"
08/07/2018 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results -Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD-"
05/08/2018 8-K Quarterly results
Docs: "Remains on track for CTX001 in β-thalassemia and sickle cell disease . After announcing the acceptance of the first Clinical Trial Application , CRISPR, together with its partner, Vertex, remains on track to initiate a Phase 1/2 trial to assess the safety and efficacy of CTX001 in patients with transfusion dependent β-thalassemia in the second half of 2018. In addition, the Company remains on track to begin clinical studies for CTX001 in SCD in 2018. CTX001 is an autologous gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies. • Continuing to advance wholly-owned allogeneic CRISPR-based CAR-T cell therapies. CRISPR remains on track to file an IND for CTX101, its lead allogeneic CAR-T cell therapy targeted toward CD19+ malignanci..."
03/08/2018 8-K Quarterly results
Docs: "Initiating Phase 1/2 trial of CTX001 in β-thalassemia in 2018. CRISPR, together with Vertex Pharmaceuticals, has filed clinical trial applications in various European countries to conduct a Phase 1/2 trial of CTX001, an autologous gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies. CRISPR has received approval for the first of these CTAs and expects to initiate clinical trials in Europe in 2018. The Phase 1/2 trial of CTX001 is designed to assess its safety and efficacy in adult transfusion-dependent β-thalassemia patients. Additionally, the Company plans to file an Investigational New Drug Application for CTX001 in SCD in the US in the first-half of 2018. • Updated preclinical data for CTX001. CRISPR presented new data at the..."
11/08/2017 8-K Quarterly results
Docs: "CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update - On track to begin first company-sponsored clinical trial of a CRISPR-based therapeutic - - Wholly-owned CRISPR-based CAR-T programs advancing rapidly -"
08/10/2017 8-K Quarterly results
05/11/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy